top of page

Rucaparib extends progression-free survival for uterine cancer patients

The results of a multisite clinical trial overseen by University of Colorado Cancer Center member Bradley Corr, MD, could offer new hope to patients with metastatic and recurrent uterine cancer, also known as endometrial cancer. The study, which was presented at the Society of Gynecologic Oncologists annual meeting this week, collected results from 79 patients at four U.S. sites over several years, shows that the oral drug rucaparib, part of a class of drugs known as PARP inhibitors, extends progression-free survival for an average of 19 months longer than surveillance alone. Surveillance is the current standard of care for uterine cancer patients who have completed the chemotherapy portion of their treatment.

Aktuelle Beiträge

Alle ansehen

Comments


bottom of page